Oromucosal Administration of Interferon to Humans
The prevailing dogma is that, to be systemically effective, interferon-alpha (IFNα) must be administered in sufficiently high doses to yield functional blood concentrations. Such an approach to IFNa therapy has proven effective in some instances, but high-dose parenteral IFNα therapy has the disadva...
Main Authors: | Manfred W. Beilharz, Joseph M. Cummins, Martin J. Cummins, Alayne L. Bennett |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2010-01-01
|
Series: | Pharmaceuticals |
Subjects: | |
Online Access: | http://www.mdpi.com/1424-8247/3/2/323/ |
Similar Items
-
Oromucosal Administration of Oxytocin: The Development of ‘Oxipops’
by: Dan Xu, et al.
Published: (2024-02-01) -
Sativex® (nabiximols) cannabinoid oromucosal spray in patients with resistant multiple sclerosis spasticity: the Belgian experience
by: Marie D’hooghe, et al.
Published: (2021-06-01) -
A Phase I Trial to Determine the Pharmacokinetics, Psychotropic Effects, and Safety Profile of a Novel Nanoparticle-Based Cannabinoid Spray for Oromucosal Delivery
by: Stefan Lorenzl, et al.
Published: (2022-01-01) -
A Review of Scientific Evidence for THC:CBD Oromucosal Spray (Nabiximols) in the Management of Chronic Pain
by: Überall MA
Published: (2020-02-01) -
Oromucosal Alginate Films with Zein Nanoparticles as a Novel Delivery System for Digoxin
by: Daniela A. Rodrigues, et al.
Published: (2021-11-01)